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Background: An important model of hepatocellular carcinoma (HCC) that has been described in southeast Asia
includes the transition from chronic hepatitis B infection (CHB) to liver cirrhosis (LC) and, finally, to HCC. The
genome-wide methylation profiling of plasma cell-free DNA (cfDNA) has not previously been used to assess HCC
development. Using MethylCap-seq, we analyzed the genome-wide cfDNA methylation profiles by separately
pooling healthy control (HC), CHB, LC and HCC samples and independently validating the library data for the tissue
DNA and cfDNA by MSP, qMSP and Multiplex-BSP-seq.
Results: The dynamic features of cfDNA methylation coincided with the natural course of HCC development. Data
mining revealed the presence of 240, 272 and 286 differentially methylated genes (DMGs) corresponding to the
early, middle and late stages of HCC progression, respectively. The validation of the DNA and cfDNA results in
independent tissues identified three DMGs, including ZNF300, SLC22A20 and SHISA7, with the potential for
distinguishing between CHB and LC as well as between LC and HCC. The area under the curve (AUC) ranged from
0.65 to 0.80, and the odds ratio (OR) values ranged from 5.18 to 14.2.
Conclusions: Our data revealed highly dynamic cfDNA methylation profiles in support of HBV-related HCC
development. We have identified a panel of DMGs that are predictive for the early, middle and late stages of HCC
development, and these are potential markers for the early detection of HCC as well as the screening of high-risk
populations.
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Human hepatocellular carcinoma (HCC) is one of the
most common primary liver malignancies; it is ranked
fifth in incidence and third in mortality among common
solid tumors worldwide [1,2]. The highest incidences are
observed in eastern Asia, where a model of multi-stage
carcinogenesis that includes progression from chronic
HBV infection (CHB) to HBV-related liver cirrhosis (LC)
and, finally, to HBV-related HCC (HBV-HCC) has been
suggested by both epidemiologic data and laboratory
investigations [3,4]. Three mechanisms are involved in
HBV-related carcinogenesis, including the following: (1)
the interruption of proper liver cell proliferation and via-
bility from HBV proteins, especially HBx [5]; (2) changes
in gene function and instability, which are induced by the
insertion of viral DNA into the host genome; and (3) gen-
omic and epigenomic injuries resulting from liver cell in-
flammation that are induced by immune T cell targeting
the HBV virus [6].
Even in the early stages of chronic hepatitis B infec-
tion, DNA methylation (DNAm) appears to be altered,
and some of these aberrant methylation patterns could
overlap with those that are associated with HCC. Some
studies have reported that the host cell modifies foreign
HBV DNA by methylation and histone acetylation, hin-
dering viral RNA replication and protein expression as
defense mechanisms against viral invasion. However, the
enhanced expression of the host DMNT also leads to the
methylation of its own CpG island (CGI), particularly for
those that are located in the promoter regions of tumor
suppressor genes (TSG), such as p16INK4A, RASSF1A,
GSTPI and MGMT as well as some miRNAs [7,8]. Previ-
ous reports have demonstrated that HBV products, in-
cluding the HBx protein, may manipulate DNMT1 to
inactivate some TSGs, such as CDH1, by the dysregulating
methylation or by aberrantly methylating miRNAs to in-
fluence downstream targets, such as DNMT3A, leading to
further disturbances in methylation [9].
Previous reports have shown that DNA methylation is
a multi-step event, which is similar to tumorigenesis
[10]. Therefore, the establishment of DNA methylation
profiles at the whole genome level, including those from
healthy control (HC) livers and CHB, LC and HCC sam-
ples, will provide fundamental information about the
common or unique DNA methylation patterns for differ-
ent stages of HCC development, which may even facili-
tate the identification of the genes that are involved in
this process.
To date, approximately five studies have reported the
DNA methylation (DNAm) profiles of HCC tumor/adja-
cent tissues using Illumina arrays [11-15]. These studies
have different sample sizes, technology and major etio-
logic causes (that is, HBV, HCV or alcohol). However,
relatively little is currently known about DNA methylationalterations that occur at the early stages of HCC develop-
ment, including those that are involved in the processes of
CHB and LC. Additionally, genome-wide methylation pro-
filing has not previously been reported for these two
pathologic models. Moreover, the invasive procedure of
tissue sampling limits the utility of this procedure for epi-
demiologic studies. In fact, CHB and LC samples are usu-
ally used as controls in genomic methylation analyses of
HCC or in-gene locus-specific CGI studies [16].
However, the biggest challenge in studying DNA me-
thylation profiling of distinct HCC stages is the im-
possibility of accessing the corresponding primary liver
tissues. In contrast, blood sampling is superior to tissue
sampling because it is minimally invasive, easy to obtain
and can be consecutively applied as serial samples in
clinical practice. Research shows that there is only a tiny
level of cell-free DNA (cfDNA) in peripheral blood cir-
culation in healthy individuals, which substantially in-
creases during the development of HCC, when high
levels of cfDNA are released into the bloodstream from
apoptotic or necrotic HCC cells. It has been reported
that increased levels of cfDNA are released into the
blood in cases of hepatitis or cirrhosis compared with
those resulting from HCC [17]. cfDNA is typically uti-
lized for gene locus-specific DNA methylation analyses,
whereas the genomic methylation profiling of cfDNA
has seldom been reported. However, the accurate iden-
tification of primary tumor genomic methylation pat-
terns in plasma cfDNA has recently been confirmed in
a study on esophageal cancer [18].
In the present study, we conducted a genome-wide
screening analysis to detect aberrant methylation events
in plasma cfDNA using the MethylCap-seq method, and
we observed some distinct DNAm alterations that were
associated with the CHB, LC and HCC developmental
stages (Figure 1). These findings enhance our under-
standing of the epigenetic disturbances in HCC plasma
and provide novel tools for assessing high-risk popula-
tions for the presence of this disease.Results
Genome-wide methylation profiling with plasma cell-free
DNA from different stages of hepatitis B virus-related
hepatocellular carcinoma development
Data mining resulted in 37,610,900; 37,072,952; 35,016,215;
33,286,609 and 33,002,633 raw reads for the samples from
the HC, CHB, LC, HCC, and NSCLC patients, respectively.
When these were mapped to the hg19 genome refer-
ence, 19,083,142; 18,285,110; 16,389,041; 14,422,110 and
14,894,363 reads were obtained, respectively, with a map-
ping rate of approximately 50% (Figure 2A, Additional
file 1: Table S4). Notably, very high background levels of
methylation were observed for the HC plasma cfDNA.
Figure 1 Overview of the experimental strategy for evaluating differential DNA methylation in various stages of hepatocellular
carcinoma development. HC, healthy control; CHB, chronic hepatitis B virus (HBV)-related hepatitis; LC, HBV-related liver cirrhosis; HCC,
HBV-related hepatocellular carcinoma (number in parentheses: participant).
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disturbances with the progressive stages of hepatocellular
carcinoma development
We used hierarchical clustering to trace the progression
of methylation disturbances during the carcinogenic pro-
cess for the HC, CHB, LC and HCC samples. The analysis
revealed the closeness of aberrant DNA methylation pat-
terns among different groups of samples (Figure 2B),
suggesting the possible sequential direction of the de-
velopment of epigenetic alterations for the samples.
Moreover, we estimated the relationships between the
aberrant methylation patterns in the various stages of
HCC development by the pairwise overlap of the peak
bases from each stage, which revealed the similarities
between HC and CHB as well as between LC and HCC
(Additional file 2: Table S5). In addition, we investi-
gated the DNA methylation densities surrounding the
transcription start site (TSS), which is a crucial region
that affects the gene expression of regulatory mecha-
nisms, and we observed an accumulation of aberrant
DNA methylation events as the disease stage progressed
from HC to CHB to LC and, finally, to HCC (or NSCLC)
(Figure 2C). These results suggest a stage-related stepwiseprocess in which the gene methylation regulatory ele-
ments were sequentially affected during the carcinogenesis
process. Collectively, the above observations indicate that
the aberrant methylation of plasma cfDNA occurs in a dy-
namic, progressive and stage-responsive manner during
HCC development. This creates the basis for our further
analyses of HCC progression-related DNA methylation
abnormalities.
Identification of differentially methylated loci among the
various stages of hepatocellular carcinoma development
To reliably obtain the DNA methylation peaks, we used
two methods, MACS and BALM. The peaks that were
generated by these two methods were generally con-
sistent (90 to 97% coincidence). We performed our ana-
lysis using these peaks, which totaled 226,898; 257,344;
282,203; 242,987 and 290,096 for the HC, CHB, LC,
HCC and NSCLC groups, respectively (Additional file 3:
Table S6).
Because our long-term aim was to establish methylation
markers that can be used for detecting and monitoring
HCC development and progression, we were particu-
larly interested in hypermethylated DNA alterations. To
Figure 2 Data mining and overall features of the MethylCap-seq libraries of plasma cfDNA during hepatocellular carcinoma (HCC)
development. (A) Analysis of the MethylCap-seq library generated 37,610,900; 37,072,952; 35,016,215 or 33,286,609 and 33,002,633 raw reads for
health control (HC), chronic hepatitis B infection (CHB), liver cirrhosis (LC), or HCC and non-small cell lung cancer(NSCLC) (blue bars), respectively.
Nearly half of the raw reads (43.3-50.7%) could be mapped to the hg19 reference genome (brown bar), producing 180,000-260,000 methylation
peaks (green bar). (B) Cluster analysis based on genome-wide DNA methylation similarities. Hierarchical clustering was conducted to show the
similarities in the DNAm among CHB, LC, HCC and NSCLC. The Euclidean distance was applied to measure the similarities in methylation
alterations. Hypermethylated regions were defined as the regions in which methylated reads were over threefold higher than those observed in
normal tissues through a 100-kb sliding window and 50-kb steps. (C) The density distribution of DNA methylation near the transcription start site
(TSS). Alterations in DNAm were surveyed over a broad region of the gene (from 200 kb downstream to 200 kb upstream of the TSS). HCC had
the highest levels of methylation in the TSS region, which was followed by LC, CHB and HC. As a control, NSCLC was plotted in the figure to
show that HCC and NSCLC had the highest levels of methylation near the TSS. The original overlapping peaks are artificially separated to enable
clear views of each peak. (D) Differential methylated regions (DMR) obtained by category, including the total DMR, gene-related DMR, CGI-related
DMR and both CGI- and gene-related DMR. (E) General characterizations of the gene structures as determined by aberrantly methylated genomic
loci in the different stages of HCC development (CHB, LC and HCC). The Y-axis depicts the hit numbers of the genes.
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we investigated the alterations at each stage, including
CHB, LC and HCC as well as NSCLC, which were com-
pared to the normal background levels of the HC. The dif-
ferent methylation peaks that were subsequently generated
are referred to as the differential methylated regions
(DMRs). The most abundant DMRs were observed in the
“total DMR” category, reflecting all of the hypermethylationpeaks that were elevated compared with the HC (Figure 2D;
Additional file 3: Table S6). In addition, the “gene-related
DMR” and “CGI-associated DMR” categories could be iso-
lated, and the category that included both the CGI and
gene-related DMRs became the focus of our further ana-
lyses (Figure 2D, Additional file 4: Table S7).
The analysis of aberrantly methylated DMRs at diffe-
rent loci in association with the HCC developmental
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tural elements were affected, which included a variety
of structural elements as defined by the UCSC Genome
Bioinformatics (UCSC) (Figure 2E and Additional file 5:
Table S8).
Early-, middle- and late-stage differentially methylated
regions and their related differentially methylated genes
To further elucidate the cfDNA methylation alterations
that occur during the CHB, LC and HCC stages, we com-
pared the DMRs that were associated with each stage on a
chromosomal distribution basis against those from the
HC (Figure 3A). The analysis showed that CHB is charac-
terized by sparse and mild hypermethylation alterations,
suggesting that certain HBV-induced epigenetic distur-
bances begin as early as this stage. However, these hyper-
methylation alterations obviously increased during the
transition from CHB to LC, indicating the presence of
more extensive epigenetic disturbances. The HCC stage
was characterized by substantial hypermethylation, and a
similar degree of epigenetic change was also observed for
NSCLC, suggesting that such alternations are commonly
associated with various malignancies in the late stages of
carcinogenesis.
Provided that the introduction of DMRs was a con-
tinuous, dynamic process during the different stages of
HCC development, we observed the following three cat-
egories of DMR involvement: 1) those that were com-
mon to CHB, LC and HCC, which may play important
roles in the process of HCC development from CHB to
HCC; because they occurred as early as the CHB stage,
we referred to them as early DMRs; 2) those that were
common to both LC and HCC, which may be essential
for the transition from LC to HCC; we called these mid-
dle DMRs; and 3) those that were unique to HCC, which
are most likely indispensible for maintaining the ma-
lignant status; we called these late DMRs. To identify
the exact genes that are affected by the aforementioned
early-, middle- and late-stage DMRs (the differentially
methylated genes (DMGs)), we used “CGI + gene” in-
volvement as the selection criterion and generated 240
early-, 272 middle- and 286 late-stage DMGs (Figure 3B,
Additional file 6: Table S9, Additional file 7: Table S10
and Additional file 8: Table S11).
Recent studies have reported that tissue and cancer-
specific DMRs occur more frequently within CGI shores,
which are regions of relatively low CpG densities that
flank traditional CGIs (up to 2 kb in distance) than within
CGIs themselves, indicating the importance of considering
CGI shores in DNA methylome analyses [19-21]. There-
fore, we generated 225 early-, 232 middle- and 259 late-
stage DMGs according to CGI involvement (Additional
file 9: Table S12, Additional file 10: Table S13 and
Additional file 11: Table S14), while a significantly expandedpanel of 1,349 early-; 1,290 middle- and 967 late-stage
DMGs were generated when CGI-shore involvement was
considered (Figure 3C, Additional file 12: Table S15,
Additional file 13: Table S16 and Additional file 14:
Table S17). This represents an obvious trend where
CGI-associated DMGs gradually increase along with
HCC progression, while CGI-shore-associated DMGs
decrease, possibly suggesting that the epigenetic effects
that occur during the late stages of HCC development
are associated with CGI alone rather than CGI-shores.
Differential methylation profiling between hepatocellular
carcinoma and non-small cell lung cancer
To locate plasma DNA methylation loci that are specific
to HCC and that may serve as potential diagnostic mar-
kers, we compared the DMGs between HCC and NSCLC
and found that 414 were shared by both malignancies,
while 462 were specific to HCC and 178 were specific
to NSCLC (Figure 3D and Additional file 15: Table S18,
Additional file 16: Table S19 and Additional file 17:
Table S20). These results suggest that although carcino-
genesis and tumor development may originate from dif-
ferent tissues, they share common DNA methylation
alterations, as well as possess unique disturbances. There-
fore, these differences can be used to determine the dif-
ferent tissue origins of carcinomas.
Functional involvement of plasma cell-free DNA
differentially methylated genes associated with
hepatocellular carcinoma developmental stages
We performed gene ontology and pathway analyses of
the early-, middle- and late-stage HCC DMGs using the
DAVID method. All of these DMGs were selected for
analysis because their promoter regions were aberrantly
methylated.
Initially, we analyzed 191 early-stage DMGs. Accor-
ding to the results, 36 GO terms were enriched in asso-
ciation with hypermethylation using this set of DMGs.
The top ten GO terms included the bioprocesses of
“cell adhesion” (four terms), “cyclase activity” (two terms),
“cytoskeleton organization” (one term), “synaptic trans-
mission” (one term), “cAMP biosynthetic process” (one
term) and “lyase activity” (one term). Our pathway ana-
lysis revealed the presence of three methylation-enriched
processes, including “neuroactive ligand-receptor inter-
action”, “androgen and estrogen metabolism” and “steroid
hormone biosynthesis” (Tables 1 and 2). Furthermore, we
characterized the GO terms for the middle-stage DMGs
and found that the 209 DMGs were associated with 71
GO terms. The top ten included “cell adhesion’ (two
terms), ‘nervous system’ (three terms), ‘collagen catabol-
ism’ (one term), ‘hormone levels’ (two terms), ‘cell-cell
signaling’ (one term) and ‘regulation of secretion’ (one
term). We found four pathways that correlated with
Figure 3 (See legend on next page.)
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Figure 3 Definition and selection of stage-specific differentially methylated region (DMR) during hepatocellular carcinoma (HCC)
development. (A) Chromosomal views of the genome-wide methylation statuses of chronic hepatitis B infection(CHB), liver cirrhosis (LC) and
hepatocellular carcinoma (HCC) and non-small cell lung cancer(NSCLC). Black bars represent hypermethylation relative to HC. DNA hypermethylation
occurs as early as the CHB stage and becomes more extensive as HCC development progresses. NSCLC, an alternative non-liver malignancy included
in this study to test effects of different organs on cfDNAm. (B) Venn diagram of the hyper-differentially methylated genes (DMGs) that occurred in the
CHB, LC and HCC stages. The diagram was used to further analyze the relationships among these three groups. (C) Gene mappings based on DMG
information. To expand upon the identification of genes that are affected during the early, middle and late stages in the DMRs, genes that were
located proximal to and involved in the hypermethylation events, such as “CGI only”, “both CGI and shore” or “shore only”, were examined. Here,
“shore” is defined as a region that flanks traditional CGIs (up to 2 kb in distance). (D) Venn diagram depicting the comparison of the hyper-DMGs that
occurred in HCC versus NSCLC. In total, 405 hyper-DMGs are shared by HCC and NSCLC, indicating the general homogeneities of the different
malignancies, such as HCC and NSCLC in this case.
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way’, ‘pathway in cancer’, ‘basal cell carcinoma’ and ‘neu-
roactive ligand-receptor interaction’ (Tables 1 and 2).
Ultimately, we found that a total of 231 late-stage
DMGs, which were representative of the advanced ma-
lignant process of hepatic neoplasia, resulted in 93 GO
terms. The top ten included ‘cell adhesion’ (four terms),
‘regionalization’ (one term), ‘developmental process’ (two
term), ‘regulation of transcription’ (two terms) and ‘regula-
tion of RNA metabolism’ (one term). In this late stage,
the two most enriched KEGG pathways were ‘neuroac-
tive ligand-receptor interaction’ and ‘pathway in cancer’
(Tables 1 and 2).
Methylation-specific PCR (MSP) screening, qMSP
validation and gene expression of the library revealed
differentially methylated genes in independent tissue DNA
Two techniques were used to assess the tissue DNA for
validating the accuracy of the plasma DNAm profile li-
brary. First, 40 DMR targets that possessed the top P
values were screened by MSP in 10 normal liver and 33
HCC (Additional file 18: Figure S2) tissue DNA samples,
generating 33 targets that were informative of HCC.
Subsequently, the informative targets were investigated
by qMSP in the same tissues sets that had supplemented
with 29 LC tissues. As expected, a substantial portion of
the targets exhibited hypermethylation in the LC, HCC
or both the LC and HCC. The typical results in selected
genes are shown in Figures 4A and B, with the UCSC
scheme of the gene information and their quantitative
methylation statues in HC, LC and HCC. These results
suggest that the altered methylation patterns that were
observed in the plasma are consistent with the respec-
tive liver tissues.
In addition, the expression levels of selected genes,
ZNF300, SLC22A20 and SHISA7, were examined using
real-time reverse transcription (RT-PCR) in the liver tissue
of HC, LC and HCC. There appeared a coincidence that
hypermethylated ZNF300 showed downregulation with
progression of HC to LC and then to HCC (P <0.05).
However, SLC22A20 and SHISA7 did not have hyperme-
thylation coupled with gene silence pattern (Figure 4C).Multiplex-BSP-seq validation of differentially methylated
genes in independent plasma cell-free DNA
To further confirm the cfDNA methylation levels, we
used Multiplex-BSP-seq on the targets that were selected
by qMSP in the independent plasma cfDNA samples
(Additional file 19: Table S2). Of the 33 target genes that
were studied, 22 were successfully amplified and deep-
sequenced. The representative results are shown in
Figure 5. For each gene, the methylation levels of seven
to ten individual CpG sites were investigated. GAPDH
and KCNV1 exhibited relatively fixed methylation pat-
terns for the seven CpGs that were inspected, regard-
less of the HCC developmental stage. Therefore, both
can serve as quality control measurements. In this
study, the methylation levels in some of the CpGs of 3
particular genes were closely related to the develop-
mental stage of HCC; therefore, they were predictive of
the disease stage. These genes and their informative
CpG sites included ZNF300 at CpG6, SLC22A20 at CpG3
and 5 and SHISA7 at CpG1, 5 and 6 (see Figure 6A, B),
which could distinguish between HC+CHB and LC +
HCC with a lower cut-off value, while distinguishing be-
tween HC+CHB + LC and HCC with a higher cut-off
value of CpG methylation (Figure 6A). When these CpG
methylation measurements were subjected to multiple
univariate logistic regression analyses, they showed strong
or very strong associations with stage discrimination (OR:
5 to approximately 14) in distinguishing between HC+
CHB and LC +HCC or between HC+CHB + LC and
HCC (Figure 6B). Taken collectively, Multiplex-BSP-seq
using an independent set of plasma samples validated
certain CpG methylation changes in a subset of genes
that were revealed by MethylCap-seq during HCC de-
velopment. This also suggests the important role of
aberrant methylation in these CpG sites during HCC
carcinogenesis.
Discussion
In the present study, methylCap-seq was applied to es-
tablish genome-wide methylation profiles in which a
cross-sectional group of HC, CHB, LC and HCC pa-
tients was recruited for a process consequence model
Table 1 GO function analysis of the DMGs in plasma cf-DNA in different stage of HCC development
Stage Term Count % PValue Genes
Early GO:0007156 ~ homophilic cell
adhesion
15 7.85 6.63E-11 PCDHGA1,PCDHGA2,PCDHA3,PCDHB5,PCDHA4,PCDHGA3,PCDHGA5,PCDHB12,
PCDHB4,PCDHGB2,PCDHGA4,PCDHGB1,PCDH17,PCDHA5,PCDHA2
GO:0016337 ~ cell-cell adhesion 16 8.38 1.53E-07 PCDH17,PCDHA2,PCDHA3,PCDHA4,PCDHA5,PCDHB5,ICAM4,PCDHB4,PCDHB12,
PCDHGA5,PCDHGA4,PCDHGA3,PCDHGA2,PCDHGA1,PCDHGB1,PCDHGB2










14 7.33 5.53E-04 MACF1,CDC42BPG,PYY,BCAR1,TCHH,ACTA1,STMN1,GRID2IP,FSCN2,PRKCZ,CYTH2,
NEFH,TNXB,SYNM
GO:0045761 ~ regulation of
adenylate cyclase activity
6 3.14 3.08E-03 HTR1A,HTR7,GNAZ,GIPR,GABBR1,ADRB1
GO:0031279 ~ regulation of
cyclase activity
6 3.14 3.52E-03 HTR1A,HTR7,GNAZ,GIPR,GABBR1,ADRB1
GO:0007268 ~ synaptic
transmission
10 5.24 3.65E-03 HTR7,PCDHB5,PCDHB4,DLGAP2,KCNC4,GRIK4,LIN7B,MTNR1B,SLC1A6,KCNN3
GO:0030817 ~ regulation of
cAMP biosynthetic process
6 3.14 3.84E-03 HTR1A,HTR7,GNAZ,GIPR,GABBR1,ADRB1
GO:0051339 ~ regulation of
lyase activity
6 3.14 3.84E-03 HTR1A,HTR7,GNAZ,GIPR,GABBR1,ADRB1
Middle GO:0007156 ~ homophilic cell
adhesion
7 3.35 2.95E-03 PCDH17,DCHS1,PKD1,PCDHGA3,PCDHGA2,PCDHGA1,PCDHGB1
GO:0019226 ~ transmission of
nerve impulse
10 4.78 1.37E-02 KCNMB3,NPBWR1,OXT,VIPR1,CHAT,SPTBN4,EGR3,SLC12A5,SLC17A7
GO:0030574 ~ collagen
catabolic process
3 1.44 1.94E-02 MMP11,MMP9,PRTN3
GO:0007628 ~ adult walking
behavior
3 1.44 2.32E-02 TRH,SPTBN4,CHAT
GO:0010817 ~ regulation of
hormone levels
6 2.87 2.39E-02 SHH,RBP1,DUOX1,FOXE1,SMPD3,ECE2
GO:0030900 ~ forebrain
development
6 2.87 2.45E-02 ID4,LHX6,SHH,ZIC5,AVPR1A,FOXG1
GO:0042445 ~ hormone
metabolic process
5 2.39 2.77E-02 SHH,RBP1,DUOX1,FOXE1,ECE2
GO:0007267 ~ cell-cell signaling 13 6.22 2.91E-02 Sep5,SLC17A7,SHH,TRH,EGR3,SMPD3,ECE2,SLC12A5,OXT,NPBWR1,VIPR1,TNFSF9,
CHAT
GO:0016337 ~ cell-cell adhesion 8 3.83 3.01E-02 PCDHGA1,SCARF2,PKD1,PCDHGA3,DCHS1,PCDH17,PCDHGA2,PCDHGB1
GO:0051047 ~ positive
regulation of secretion
5 2.39 3.03E-02 Sep5,TRH,OXT,SCAMP5,AVPR1A
Late GO:0007156 ~ homophilic cell
adhesion
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Table 1 GO function analysis of the DMGs in plasma cf-DNA in different stage of HCC development (Continued)






















11 4.76 1.75E-05 PAX1,HOXC4,LHX1,GBX2,TBX3,PCDH8,TCF15,MYF6,CYP26C1,HOXD4,GATA4
GO:0006355 ~ regulation of
transcription, DNA-dependent




GO:0051252 ~ regulation of
RNA metabolic process




GO:0045449 ~ regulation of
transcription
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malignancy group. Plasma cfDNA was collected from
these individuals for the analyses. Because of the minute
quantities of cfDNA that were obtained, MethylCap-seq
analyses could not be performed individually; instead, the
cfDNA was pooled. In fact, sample pooling has been used
in a number of -omic studies because it is cost-efficient
and suitable for scarce sample models [22,23].Table 2 KEGG pathway analysis of the DMGs in plasma cf-DN




hsa00150:Androgen and estrogen metabolism 3 1.57 4.0
hsa00140:Steroid hormone biosynthesis 3 1.57 5.9
Middle hsa04020:Calcium signaling pathway 6 2.87 2.6
hsa05200:Pathways in cancer 7 3.35 9.3







hsa05200:Pathways in cancer 8 3.46 1.8In this experiment, we initially explored the features
of genome-wide DNA methylation profiling by cluster
analyses and found similarities between the patterns of
aberrant DNA methylation for the different HCC devel-
opmental stages, which resembled the natural course of
this disease. Hence, our study model can be used to assess
the patterns of DNA methylation alterations in cfDNA












Figure 4 Quantitative methylation-specific PCR (qMSP) and gene expression test of MethylCap-seq library data using tissue DNA and
RNA templates. The screening analysis generated a set of 33 genes that are informative of hepatocellular carcinoma (HCC). This set of genes
was further analyzed by qMSP and gene expression using real-time PCR in DNA and RNA samples from 10 health control (HC), 29 liver cirrhosis
(LC) and 30 HCC tissues. Three representative gene results are shown here. A) The UCSC scheme of the gene locus and examined promoter
region are shown as well as the methylation information in HC, chronic hepatitis B infection (CHB), LC and HCC groups. B) Quantification of the
methylation status in HC, LC and HCC. C) Relative gene expression assay by RT-PCR in HC, LC and HCC. For statistical significance, *P <0.05;
**P <0.01; ***P <0.001; NS, not significant.
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hypermethylation in HCC relative to HC, with data that
on tissue DNA. Shen et al. [15] analyzed HCC tumor and
adjacent non-tumor tissues from 62 Taiwanese HCC cases
using Illumina methylation arrays and found that 684
CpG sites in 550 genes were significantly hypermethy-
lated in the tumor tissues. In fact, 343 of the genes from
that study were detected in our plasma HCC analysis
(Additional file 20: Table S21) in spite of the different ana-
lysis methods and different samples used in both inves-
tigations. Therefore, these identical genes may serve as
good resources for selecting plasma markers for HCC
evaluations because they exhibit hypermethylation not
only in the tissues but also in the cfDNA; therefore, the
cfDNA methylation alterations parallel those of hepatic
cells.
According to the accepted hypothesis, aberrant DNA
methylation in association with carcinoma is characte-
rized by genome-wide hypomethylation and clustered
hypermethylation [24,25]. Therefore, we analyzed the rela-
tionship between HCC stage-related DMRs and gene pro-
moters and observed that the DMRs were more abundantin the promoters during the advanced stages of HCC de-
velopment than in the early stages, and the highest con-
centrations were present in the promoter regions for HCC
and NSCLC. In terms of HCC development progres-
sion, we found 240 early-, 272 middle- and 286 late-stage
DMGs. These results indicate that HBV invasion led to
hypermethylation in the genomic DNA of the hepatic
cells, and some of these alterations could be maintained
as late as the HCC stage, which is presumably because
they are the important factors for HBV-related HCC
development. In addition, these results suggest that the
alterations gradually accumulated, rather than appear-
ing all at once, during the HBV-related HCC progres-
sion. It is possible that the late-stage DMGs are the
driving factors underlying, or are merely consequences
of, the hepatic cell malignant transformations that occur
during HCC development.
Knowledge of the functional involvement of aberrantly
methylated genes is important to understanding the me-
chanisms that occur during HCC development. We per-
formed GO and pathway analyses on DMGs from the
early, middle and late stages of HCC development. The
Figure 5 Representative results of the quantitations of the methylation levels by Multiplex-BSP-seq for health control (HC), chronic
hepatitis B infection(CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) plasma DNA samples. For each gene, the heat map of
the methylation patterns for each CpG is shown. The methylation level (%) measured at each individual CpG site is expressed by the percentage
of methylated CpG versus unmethylated CpG sites. HC, CHB, LC and HCC are represented by colored areas of blue, green, violet and red,
respectively. The colored area is defined by 25%/75% quantiles. The comparison of the CpG methylation levels for each stage is colored blue to
red, in small squares, to indicate the different P values. Representative heat map and methylation plot analysis of 5 target genes; consistently low
levels of methylation of all CpGs were observed in GAPDH and steady high levels of CpG(CG1,2 and 7) methylation in KCNV1 are independent of
the HCC developmental stage, while the methylation statuses of the other 3 genes (ZNF300, SLC22A20 and SHISA7) varied according to the
developmental stage.
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minence of the ‘cell-adhesion’ and ‘neuroactive ligand-
receptor interaction’ pathways. In a previous study, the
regulatory profile of the HBx gene was investigated, and
six pathways were deregulated, including ‘neuroactive
ligand-receptor interaction’ and ‘cell adhesion molecules’
[26]. Another study investigated hypermethylated genes
in single hepatocytes from HBV-related HCC, and the
top KEGG pathway was identified as the ‘neuroactive
ligand-receptor interaction’ [27]. All of these results sug-
gest the extraordinary importance of the ‘neuroactive
ligand-receptor’ pathway in HCC carcinogenesis. With re-
spect to the two sex hormone metabolism-related path-
ways, ‘steroid hormone biosynthesis’ is a direct target of
HBx [26]. Moreover, HCC predominantly occurs in males
[28], and these results suggest that the gender involvement
may be mediated by epigenetic disturbances in the steroid
hormone metabolism and that these alterations may
occur in the early stages of HBV-HCC progression. Theappearance of the GO terms for ‘cell adhesion’ and ‘neuro-
active ligand-receptor interaction’ in the middle-stage and
early-stage DMGs suggest that they play indispensable
roles during the early and middle stages of HCC develop-
ment. In addition to these two inherited items, some other
GO terms, including ‘nerve system’, ‘collagen and hor-
mone’ and ‘cell signaling,’ are possibly responsible for
the extensive pathogenesis in liver cirrhosis. The ‘cal-
cium signaling pathway’ in this stage was also identified
in other similar studies [26,27]. The analysis of late-
stage DMGs revealed the prominence of ‘cell adhesion,’
which was the top GO term, but other categories, such
as the ‘developmental process’, ‘regulation of transcription’
and ‘regulation of RNA metabolism,’ may also be tightly as-
sociated with the malignant growth potential of HCC. Not-
ably, the ‘neuroactive ligand-receptor interaction’ pathway
was identified throughout the developmental stages, em-
phasizing its persistent role in HBV-related carcinogenic
processes. We further isolated the plasma DMGs that
Figure 6 Receiver operating characteristics (ROC) and multiple univariate logistic regression analyses for using CpGs to distinguish
between hepatocellular carcinoma (HCC) developmental stages are shown according to the CpG position and disease stage (HC + CHB
versus LC + HCC or HC + CHB + LC versus HCC). (A) Receiver operating characteristic (ROC) curves for ZNF300, SLC22A20 and SHISA7.
Complete DNA methylation data from all four stages of HCC development were used to construct the ROC curves. The ROC curves plot the
sensitivity versus 100-specificity. Upper panel: a lower cut-off value was used to distinguish between (LC + HCC)/ (HC + CHB).Lower panel: a higher
cut-off value was used to distinguish between HCC/(HC + CHB + LC). (B) A multiple univariate logistic regression analysis was performed using
the CpG methylation patterns to evaluate the association between gene methylation and the stage of HCC development. Relationship between
the CpG methylation (odds ratios) and the developmental stage. To separate (LC + HCC)/ (HC + CHB) and HCC/(HC + CHB + LC), both univariate
(which considers the methylation levels) and multivariate (which also considers the age and gender) logistic regressions were performed using
CpG methylation data for ZNF300, SLC22A20 and SHISA7.
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related HCC development, which may be involved in
particular GO functions and pathways related to HCC.
The DNA methylation patterns that we observed may
play important roles in HCC development and facilitate
early tumor diagnosis, disease progression monitoring
and the identification of high-risk individuals. To fur-
ther understand these findings, we used a combination
of Multiplex-BSP-seq, Illumina index adaptor techniques
and deep sequencing to validate 33 DMG targets in ap-
proximately 160 cfDNA samples from four stages of HCC
development. This resulted in the identification of three
relevant genes (SHISA7, ZNF300 and SLC22A20) in asso-
ciation with ten CpG methylation statuses that were in-
formative of HBV-related HCC development. Similar to
the methylation patterns observed in the MethylCap-seqanalysis, Multiplex-BSP-seq also revealed higher similar-
ities between HC and CHB as well as between LC and
HCC, suggesting close relationships between their patho-
genic processes in terms of epigenetic involvement. Epi-
genetic changes occurred gradually from HC to CHB and
more substantially from CHB to LC. The accumulation of
alterations slows in the transition to the final malignant
state of HCC, and the entire process is not likely to occur
at a steady rate as indicated by this study.
Epigenetics plays a role through regulating the corre-
sponding gene expression. In our present study, the in-
creasing hypermethylaton of gene ZNF300, during HCC
development, is coupled with decreased gene expres-
sion. However, the remaining two genes, SHISA7 and
SLC22A20, failed to have this correlation. These re-
sults might suggest that only a subset of hypermethylated
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silence pathway, while most of the remaining hyper-
methylated genes influence tumor development by al-
ternative mechanisms.
The ROC analysis of these ten CpGs revealed that LC
and HCC could be distinguished from HC and CHB
when a lower methylation cut-off value was used, while
HCC could be effectively discriminated from HC, CHB
and LC when a higher methylation cut-off value was
adopted. Univariate and multivariate logistic regression
analyses indicated the strong association of these CpG
methylation sites with LC and HCC, suggesting that
these aberrant DNA methylations may represent risk
factors for HCC development. Other researchers have
reported that the DNA methylation patterns of single
CpG bases may be useful indicators of carcinoma
risk and development [29].
With respect to the three aforementioned genes,
SLC22A20, which is located on chromosome 11q13.1,
belongs to a family of transmembrane proteins that
function as organic anion transporters by accepting a
variety of chemically unrelated endogenous and ex-
ogenous anions, including many popular drugs [30,31].
To date, there no previous reports have described the
association of this gene with malignant tumors. We
speculate that the aberrant methylation of this gene
leads to the dysregulation of its expression, which con-
tributes to HCC development from the accumulation
or depletion of anions or pH alterations in the microen-
vironments of the hepatic cells. ZNF300, which is loca-
ted on chromosome 5q33.1, possesses an amino-terminal
KRAB domain and 12 carboxyl-terminal C2H2 zinc finger
motifs. ZNF300 is localized to the nucleus, and the KRAB
domain of this protein has transcription repressor activ-
ities. These results suggest that ZNF300 is a ubiquitous
transcription repressor in the nucleus [32]. Additionally, it
has been reported to promote tumor development by
modulating the NF-KB pathway, in which it plays an im-
portant role during tumor development in inflamed tis-
sues [33]. The prevalence and molecular mechanisms
underlying inflammation have been extensively studied
because inflammation is a risk factor for a subset of tu-
mors. Furthermore, the invasion of hepatic cells by
HBV results in inflammation, which accompanies LC
and may later progress to HCC, and the involvement of
ZNF300 in this process requires further study. SHISA7,
which is located on chromosome 19q13.42, belongs to
the SHISA family, but its exact function is unknown.
The high overlap of these three genes in LC and HCC
in terms of their methylation levels suggests that they
have important roles in the progression from LC to
HCC, defining them as pro-oncogenes or HCC-driven
genes; however, more investigations are needed to for-
mulate definitive conclusions.Conclusions
In summary, our present study on serum cfDNA methy-
lation provides the following hypothesis, which could be
validated: chronic HBV infection of hepatic cells triggers
a series of aberrant DNA methylations that accompany
the entire process of HBV-related HCC carcinogenesis,
including the gradual accumulation of abnormal DNA
hypermethylation. The affected gene targets have the po-
tential to be both diagnostic biomarkers and therapeutic
targets for HCC treatment.Methods
Patient samples
With informed consent and the approval of the Medical
Institutional Review Board of Renji Hospital and Shanghai
Chest Hospital, Shanghai Jiao Tong University, patient
specimens were collected between 2010 and 2012. Three
separate sets of patient samples were obtained to estab-
lish the genome-wide methylation profiles of the plasma
cfDNA by MethylCap-seq, screen and identify candidate
differential methylation regions (DMRs) in tissue DNA by
MSP/qMSP and validate candidate DMRs in plasma
cfDNA by Multiplex-BSP-seq. The first set of samples in-
cluded 31 HC, 30 CHB, 27 LC and 29 HCC cases in
addition to 26 non-small cell lung cancer (NSCLC) sam-
ples, which were included as a control, representing a ma-
lignancy from a separate organ. The second set of samples
included 10 HC, 29 LC and 33 HCC cases. The HC liver
samples were obtained from biopsy tissues, from which
other common liver pathological changes were excluded.
The LC sample was also obtained from biopsy tissue, and
a pathologist confirmed the HCC sample via histological
verification. The third set of samples included 37 HC, 36
CHB, 40 LC and 47 HCC cases. All patients were HBV-
positive with the exception of the NSCLC patient. No sig-
nificant differences were found between the study groups
in terms of age or gender. The LC patients who were re-
cruited for this study were excluded if they also suffered
from autoimmune diseases and/or alcoholic cirrhosis. The
blood samples were stored at 4°C before plasma separ-
ation, and the tissue samples were stored at -80°C until
DNA extraction. More detailed clinical information is
provided in Table 3.
In this study, group of patients were recruited by fol-
lowing criteria:
CHB (chronic HBV-related hepatitis) patient recruit-
ment: more than 6 month history of diagnosed or sus-
pected acute hepatitis; laboratory test evidence of HBV
infection; mild to moderate increase of alanine amino-
transferase (ALT) over years; no serious manifestations
outside of hepatic system.
HC (healthy control) recruitment: individuals who at-
tended routine healthy examinations; no histories of
Table 3 Clinicopathological features of patient and healthy controls in the present study
Plasm methylome Tissue qMSP Plasm BSP
HC1 CHB2 LC3 HCC4 NSCLC5 HC1 LC3 HCC4 HC1 CHB2 LC3 HCC4
Cases 31 30 27 29 26 10 29 33 37 36 40 47
Gender
Male 28 (90.3%) 27 (90.0%) 24 (88.9%) 26 (89.7%) 23 (88.5%) 6 (60%) 25 (86.2%) 27 (84.9%) 30 (81.1%) 28 (77.6%) 33 (78.8%) 39 (83.0%)
Female 3 (9.7%) 3 (10.0%) 3 (11.1%) 3 (10.3%) 3 (11.5%) 4 (40%) 4 (13.8%) 6 (15.1%) 7 (18.9%) 8 (22.2%) 7 (21.2%) 8 (17.0%)
Age 50.3 ± 8.6 50.7 ± 7.6 50.8 ± 9.6 55.8 ± 8.5 52.4 ± 9.6 42.2 ± 6.53 46.9 ± 9.2 50.3 ± 9.1 53.32 ± 5.3 52.53 ± 4.7 48.89 ± 10.7 54.29 ± 8.3
HBV infection
Yes 0 (0%) 30 (100%) 27 (100%) 29 (100%) 0 (0%) 0 (0%) 30 (100%) 33 (100%) 0 (0%) 36 (100%) 40 (100%) 47 (100%)
No 31(100%) 0 (0%) 0 (0%) 0 (0%) 29 (100%) 10(100%) 0 (0%) 0 (0%) 37 (100%) 0 (0%) 0 (0%) 0 (0%)
Differentiation
Poor / / 11 (37.9%) 12 (46.2%) / / 15 (45.5%) / / / 22 (46.8%)
Moderate / / 10 (34.5%) 8 (30.7%) / / 13 (39.4) / / / 15 (31.9%)
High / / 8(27.6%) 6 (23.1%) / / 5 (15.1%) / / / 10 (21.3%)
Tumor stage
I/II / / 14 (48.3%) 10 (38.5%) / / 13 (39.4%) / / / 12 (25.5%)
III/IV / / 15 (51.7) 16 (61.5%) / / 20 (60.6%) / / / 35 (74.5%)
Tumor size
≤3cm / / 16 (55.2%) / / / 11 (33.3%) / / / 16 (34.1%)
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findings for hepatic biochemical tests.
HCC (HBV-related hepatocellular carcinoma) patient
recruitment: pathological or clinical evidence indicating
HCC diagnosis; chronic HBV related hepatitis or long-
term HBV infection; normal or mildly abnormal liver bio-
chemical examinations; no serious dysfunction in kidney,
heart, lung, brain and other organs.
LC (HBV-related liver cirrhosis) patient recruitment:
pathology or imaging diagnoses of cirrhosis patients; over
a year of expected survival (liver function at level A or B
by Child, MELD score ≤10); histories of chronic HBV
infection or long-term hepatitis B infection; normal or
mildly abnormal liver biochemical examinations; nor-
mal or slightly elevated serum AFP levels (≤20μg/L).
NSCLC (non-small cell lung cancer) patient recruit-
ment: pathological or clinical diagnoses of lung cancer;
no histories of hepatitis; no positive findings of HBV
hepatitis infections by related blood tests; no abnormal
findings in liver biochemical tests; no obvious dysfunc-
tions in renal, heart, liver, brain or other organs.
Slash represents missing data.DNA and RNA extraction
A peripheral venous blood sample was drawn into an
EDTA tube for each subject, and the plasma sample was
separated within 2 hours. The plasma was isolated by
centrifugation of the whole blood at 2,500 × g for 10
min. To eliminate potential cellular debris, an additional
centrifugation step was performed at 15,000 × g for 10
min [34]. The cfDNA was extracted from 800-μl aliquots
of plasma using the Qiagen Blood DNA Kit (QIAGEN,
Hilden, Germany). The tissue DNA was isolated from
100 mg of corresponding tissues using a conventional
proteinase K/organic extraction method as previously
described [35]. The extraction of total RNA from liver
tissue and reverse transcription were performed as de-
scribed in reference [36].Processing of MethylCap-seq
To obtain adequate starting material for the MethylCap-
seq library, 30 ng of plasma cfDNA from each partici-
pant were pooled for each group. Approximately 500 ng
of DNA for each of the five libraries (HC, CHB, LC,
HCC and NSCLC) was sonicated until all of the DNA
fragments were within the desired size range (100 to
200 bp). The end-repair, adenosine base addition and
adaptor ligation steps and methylated DNA enrichment
were performed as previously described [37]. Finally, 1 μg
of each product was placed in the Genome Analyzer II
(Illumina, Inc., San Diego, CA) to generate 36 bp-long un-
paired reads. The resulting data were processed to gener-
ate genomic methylation profiles and then uploaded to apublic database (Gene Expression Omnibus: GSE54961
(2014)).
Processing of MethylCap-seq data and GO analysis
We used the BWA alignment tool [38] with the default
settings to map the 36-bp unpaired reads to the hg19
human genome reference assembly [39]. After removing
the PCR duplicates with Picard (http://broadinstitute.
github.io/picard/), SAMtools and Picard were used to
convert, sort and index the aligned data. The DMRs in
the four observed groups (CHB, LC, HCC and NSCLC)
for comparison with the HC were identified using two
methods, MACS [40] and BALM [41], to increase the
power of detection for the MethylCap-seq analysis.
Methylation peaks (hypermethylated regions) were iden-
tified using MACS for the four observed groups and HC,
respectively, as previously described [37]. For BALM, a
dual-threshold strategy was applied to decrease the false-
positive detection of the DMRs. A high-confidence thresh-
old of 0.975 for the four observed hypermethylated re-
gions and a low-confidence threshold of 0.95 for the HC
hypermethylated regions were set. Then, the specific
methylation peaks of the four observed groups were de-
fined as the hypermethylated regions. Similarly, HC-
specific methylation peaks were defined as hypomethy-
lated regions using the reverse setting. Whole-genome
methylation (methylation of each CpG) was inferred with
BALM, which was processed to perform Pearson correl-
ation analyses among all of the samples using the R soft-
ware. The refSeq genes (UCSC genes) and corresponding
CpG islands (CGIs) were downloaded from the table
browser of the UCSC database [39]. The BED files were
manipulated with Bedtools [42] in addition to assorted
Perl scripts.
Screening with methylation-specific PCR (MSP) and
validation with qMSP
The tissue DNA and cfDNA were converted with sodium
bisulfite using an EpiTect Kit (QIAGEN, Hilden,
Germany). All of the DNA (converted or unconverted)
samples were immediately stored at -80°C for further ana-
lyses. Methylation-specific PCR (MSP) primer pairs were
designed using online software (http://www.urogene.org/
cgi-bin/methprimer/methprimer.cgi; Additional file 21:
Table S1). In total, 40 MSPs were performed, and the re-
sults were visualized on gels. The MSP products were
cloned by T-Vectors and verified by sequencing. The
in vitro methylated DNA from the HepG2 cells was ob-
tained using the CpG (M. SssI) methyltransferase (NEB,
MA,USA) treatment and used as a positive control. Water
was used as a non-template control. Up to 33 gene targets
were measured using methylation-specific real-time
PCR (qMSP) as previously described [43]. In brief, the
PCR products of the methylated and unmethylated
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T Easy Vectors (Tiangen, Beijing, China). The plasmids
were diluted, and a standard curve was constructed to
measure both the methylated and unmethylated targets.
Real-time PCR was conducted with the Rotor-Gene Q
(QIAGEN, Valencia, CA). Target gene methylation was
calculated using the following formula: 100 ×methylated
reaction/(unmethylated reaction +methylated reaction).Multiplex-BSP-seq
The BSP regions were situated within the regions that were
assessed by the qMSP analysis. BSP amplicons that were 80
to 120 bp in size were obtained because of the fragmenta-
tion of the cfDNA template. The BSP primer pairs were de-
signed using online software (http://www.urogene.org/cgi-
bin/methprimer/methprimer.cgi; Additional file 19: Table
S2). Degenerate primers were utilized in the promoter re-
gions in case there where inevitably contained CpG sites.
To overcome the difficulties that are associated with the
scarcity of cfDNA, Multiplex-BSP-seq was performed. In
total, 35 BSP primers were divided into three panels accord-
ing to their annealing temperatures. Three independent
multiplex-PCR amplifications were conducted for each
cfDNA sample, and the three PCR products were combined
in equal amounts as determined by gel electrophoresis
and Qubit for ligation with a barcode adaptor (oligo-
nucleotide sequences © 2007-2012 Illumina, Inc. All rights
reserved). A final pooling, which contained equal quan-
tities of each participant, was performed with all of the
ligation products, and 12 cycles of PCR were performed
using library amplification primers to produce the tem-
plates for deep sequencing. Illumina HiSeq 2500 was
used to generate 100-bp paired-end reads (Additional
file 22: Figure S1). The mapping of the raw reads was per-
formed by Bismark (version 0.7.7) and Bowtie2 (version
2.0.5), and the resulting SAM data were sorted by SAM-
tools. The R methylKit package was utilized to assess the
methylation levels at each CpG locus with default settings
unless otherwise specified. The methylation level (%)
that was measured at each individual CpG site was
expressed as the percentage of methylated CpG versus
unmethylated CpG.Real-time reverse transcription PCR
The expression levels of selected genes were measured
by real-time quantitative RT-PCR analysis. Three or
more reactions were performed for each sample using a
RealMasterMix (SYBR Green) kit (TianGen, Beijing,
China) with gene-specific primers (Additional file 23:
Table S3) on a Rotor-Gene Q (QIAGEN, Valencia, CA).
The RNA quantity was normalized to the ACTB content,
and gene expression was quantified according to the 2-ΔCt
method.Statistical analyses
To evaluate the assay’s potential for discriminating bet-
ween different disease stages, the data that were obtained
for the HC, CHB, LC and HCC samples were used to
calculated the optimal cut-off value using the most sig-
nificant area under the receiver operating characteristic
(ROC) curve. Univariate models were used to examine
the association between the gene CpG methylation and
HCC stage. Multivariate models were then developed
that adjusted for the most important covariates, including
age and gender. The measurement data were analyzed
using a one-way ANOVA. The sample means were com-
pared with an unpaired t-test, assuming unequal vari-
ances, and all of the tests were two-tailed. P values are
shown for statistically significant findings. All of the statis-
tical analyses were performed using the SPSS statistical
package (version 13.0, Chicago, IL, USA).Additional files
Additional file 1: Table S4. Data mining of plasma cfDNA MethylCap-seq
libraries (1).
Additional file 2: Table S5. Pairwise overlap of bases of peak regions
for each sample as indicated by BALM and MACS.
Additional file 3: Table S6. Data mining of plasma cfDNA MethylCap-seq
libraries (2). *peaks are considered to be shared when they have overlapping
regions.
Additional file 4: Table S7. Data mining of plasma cfDNA MethylCap-
seq libraries (3).
Additional file 5: Table S8. General characteristics of aberrant
methylation patterns according to UCSC genomic context definitions.
Additional file 6: Table S9. Plasma cfDNA DMGs belong to early stage
of HCC carcinogenesis progression. ※logarithmic transformations of P
values to show significance levels of differentially methylated regions (for
DMR estimations) or methylation blocks (for MACS). Higher values
indicate higher probabilities of DMR or methylation blocks.
Additional file 7: Table S10. Plasma cfDNA DMGs belong to middle
stage of HCC carcinogenesis progression.
Additional file 8: Table S11. Plasma cfDNA DMGs belong to late stage
of HCC carcinogenesis progression.
Additional file 9: Table S12. Early HCC development-associated DMGs
in cfDNA as determined by genomic CGI involvement.
Additional file 10: Table S13. Middle HCC development-associated
DMGs in cfDNA as determined by genomic CGI involvement.
Additional file 11: Table S14. Late HCC development-associated DMGs
in cfDNA as determined by genomic CGI involvement.
Additional file 12: Table S15. Early HCC development-associated
DMGs in cfDNA as determined by genomic CGI-shore involvement.
Additional file 13: Table S16. Middle HCC development–associated
DMGs in cfDNA as determined by genomic CGI-shore involvement.
Additional file 14: Table S17. Late HCC development-associated DMGs
in cfDNA as determined by genomic CGI-shore involvement.
Additional file 15: Table S18. Plasma cfDNA DMGs shared between
HCC and NSCLC.
Additional file 16: Table S19. Plasma cfDNA DMGs in HCC after
deletion of NSCLC DMGs.
Additional file 17: Table S20. Plasma cfDNA DMGs in NSCLC after
deletion of HCC DMGs.
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hyper-DMRs in HCC development. MSP screening of 40 hyper-DMR
targets in 30 HCC and 10 HC and qMSP validation of 33 hyper-DMR
targets in same set of HCC and HC plus 29 LC. Row, the gene target
investigated; column, the sample DNA; MSP, positive or negative category
result. qMSP, continuous measurement result.
Additional file 19: Table S2. Primer sets of Multiplex-BSP-seq analysis
of candidate genes.*CpG dinucleotides flanked by BSP primers were
counted . # for degenerate primer. Y = C/T and R = A/G.
Additional file 20: Table S21. Comparison of hypermethylation DMGs
in plasma cfDNA from this study with hypermethylated CpG probe sites
in HCC tissues that were reported by Shen et al. [15]. *differentially
hypermethylated regions in HCC relative to HC. ※P values associated
with relationship between DMRs in HCC cfDNA and CpG identities in
450,000 sites as reported by Shen et al. [15].
Additional file 21: Table S1. Primer sets for MSP and qMSP analyses of
candidate genes.
Additional file 22: Figure S1. The process of Multiplex-BSP-seq.
Additional file 23: Table S3. Primer sets for RT-PCR.
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